Division of Hepatology The Division of Hepatology is active in all critical aspects of care for adult patients with liver disease. Clinicians work diligently to evaluate and care for patients undergoing liver transplantation, while skilled researches investigate cutting edge therapies that dramatically impact treatment options for patients. Paul Martin, MD Division Chief Professor of Medicine
DIVISION FACULTY LIST Professors of Medicine Lennox J. Jeffers, MD Paul Martin, MD Christopher B. O’Brien, MD Eugene R. Schiff, MD Associate Professors Cynthia Levy, MD Assistant Professors Leopoldo B. Arosemena, MD Kaylan R. Bhamidimarri, MD, MPH Patricia D. Jones, MD, MSCR Maria D. Hernandez, MD Eric F. Martin, MD
24
Since joining the University of Miami in August 2015, Dr. Jones has analyzed the survival time in patients diagnosed with HCC at Sylvester Comprehensive Cancer Center, University of Miami Hospital and Jackson Memorial Hospital, and found significant differences in survival by race. This research was presented at Digestive Disease Week 2016 and featured on the NBC National News REVEALING STARKLY DIFFERENT website in an article entitled, “Study Finds OUTCOMES BY RACE Blacks More Likely to Die From Liver Cancer.” Coming on the heels of significant advances Dr. Jones is currently analyzing the made in the treatment of liver disease in the outcomes of HCC in the state of Florida and last several years, the recruitment of Dr. will be analyzing institutional practices on Patricia Jones to the faculty has resulted in a screening high risk patients for hepatitis B as major expansion of activity in tackling one of well as HCC. She was awarded the Jay Weiss the next important challenges, hepatocellular Institute for Health Equity Pilot Grant through carcinoma (HCC). With effective therapies for Sylvester Comprehensive Cancer Center and hepatitis C and with vaccination reducing the in collaboration with the Disparities and burden of hepatitis B in the United States, the Community Outreach Core will be conducting major therapeutic challenge in liver disease focus groups of Blacks born in the US and will be the prevention and treatment of NonHaiti to understand perceptions of hepatitis B, alcoholic fatty liver disease (NAFLD). In chronic liver disease and HCC. addition to changing causes of cirrhosis, HCC The Division anticipates this work will is the other major complication of liver disease enable the delivery of personalized care to and is now the tumor with the greatest increase vulnerable populations and impact liver cancer in frequency in the United States. outcomes both by preventing cancer from developing and improving the treatments Below: Dr. Patricia Jones analyzes disparities in outcomes for available for those who develop cancer. hepatocellular carcinoma patients
U H ea l t h | U n i v er s i t y o f M i a m i M i l l er Sc hool of Med i c i ne